ストックスクリーナーアプリを入手
2.94
2.49%
-0.07
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates - BioSpace
ImmunityBio Announces $80 Million Securities Purchase - TipRanks
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors - Business Wire
Is ImmunityBio Inc. a good long term investmentMarket-leading profit generation - Autocar Professional
ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency - MSN
What analysts say about ImmunityBio Inc. stockHigh-yield market plays - Autocar Professional
What drives ImmunityBio Inc. stock priceConsistently high yield - jammulinksnews.com
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper - Benzinga
ImmunityBio: A High-Conviction Play on ANKTIVA's Expanding Indication and Immune-Boosting Platform - AInvest
ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval - Seeking Alpha
ImmunityBio Inc. Stock Analysis and ForecastSkyrocketing returns - jammulinksnews.com
ImmunityBio’s Anktiva Rollercoaster: From FDA Rejection and 55% Stock Drop to Approval - TradingView
ImmunityBio Settled With Investors Over FDA Rejection Drama— How to Claim Your Share - TradingView
ImmunityBio: High Stakes On ANKTIVA's Growth Amidst FDA Friction And Financial Pressures - Seeking Alpha
ImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study Update - TipRanks
Bullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA Authorization - MSN
ImmunityBio Stock Surges Amid Promising Trial Updates - TipRanks
ImmunityBio’s Innovative Approach to Bladder Cancer Treatment: A Clinical Study Update - TipRanks
ImmunityBio Granted UK Approval for Bladder Cancer Treatment - MarketScreener
ImmunityBio: D. Boral Capital Maintains Buy, Raises PT to $30 from $30 - AInvest
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Lelezard
ImmunityBio's ANKTIVA® Secures UK Approval: A Catalyst for Global Oncology Leadership - AInvest
Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
13 Stocks Under $5 With High Upside Potential - Insider Monkey
UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication - MarketScreener
ImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial Success - Insider Monkey
ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA - Yahoo Finance
Anktiva Approved For Additional Treatment - Los Angeles Business Journal
ImmunityBio Approves 2025 Equity Incentive Plan - TipRanks
ImmunityBio's $10.5M Investor Deal Gets Final OK - Law360
ImmunityBio Gets Final OK for $10.5 Million Investor Settlement - Bloomberg Law News
ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bladder cancer treatment - pharmaphorum
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry - newswire.ca
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Jumps 18% on Anktiva Access Expansion - MSN
15 Stocks That Stole The Show Last Week - Insider Monkey
Deadline to Claim Your Payout from the $10.5M ImmunityBio Settlement Is in 1 Month - TradingView
Why ImmunityBio, Inc. (IBRX) Skyrocketed Today - Yahoo Finance
1.74%
0.00%
大文字化:
|
ボリューム (24 時間):